Trial Profile
A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Umitrelimorgene autodencel (Primary) ; Diphtheria-tetanus vaccine; GM-CSF gene therapy; Temozolomide
- Indications Astrocytoma; Glioblastoma
- Focus Therapeutic Use
- Acronyms ATTAC-II
- 05 Dec 2023 Status changed from active, no longer recruiting to completed.
- 26 Oct 2023 Planned End Date changed from 1 Sep 2024 to 1 Sep 2026.
- 15 Sep 2023 Planned End Date changed from 1 Jun 2024 to 1 Sep 2024.